The efficacy of a Flurbiprofen drug intervention on the relief of sore throat due to upper respiratory tract infection.
A multi-centre, randomised, double-blinded, placebo-controlled, parallel group, multiple dose, study of the efficacy of 8.75 mg flurbiprofen micro granules in the relief of sore throat due to upper respiratory tract infection.
Reckitt Benckiser Healthcare (UK)
370 participants
May 10, 2009
Interventional
Conditions
Summary
This study is testing a new treatment for sore throat called flurbiprofen micro granules. Flurbiprofen lozenges are approved by the Australian health authority, the Therapeutic Goods Administration (TGA) for the relief of pain, swelling and inflammation due to severe sore throat. In this study, tiny granules of flurbiprofen will be tested to determine if they too are effective in the relief of sore throat.
Eligibility
Inclusion Criteria6
- Age: 18 to 75.
- Both male and female patients may be included.
- Primary diagnosis: Patients with sore throat of onset within the past 4 days
- Patients who have a sore throat (greater than or equal to 6) on the Throat Soreness Scale at baseline.
- Objective findings that confirm the presence of tonsillopharyngitis (greater than or equal to 5 points on the expanded 21-point Tonsillopharyngitis Assessment).
- Patients who have given written informed consent.
Exclusion Criteria23
- Any previous history of allergy or known intolerance to the study drug or the following formulation constituents xylitol, mannitol, carbomer 974P, sodium bicarbonate, mint, peppermint, aspartame, citric acid, silicon dioxide
- Those whose sore throat has been present for more than 4 days.
- Those who have evidence of mouth breathing.
- Those who have evidence of severe coughing.
- Those who have any disease that can compromise breathing e.g. bronchopneumonia.
- Those who have taken any medicated confectionary, throat pastille, spray, or any product with demulcent properties such as boiled sweets in the previous 2 hours.
- Those who have used any sore throat medication containing a local anaesthetic within the past 4 hours.
- Those who have used any analgesic, antipyretic or cold medication (e.g. decongestant, antihistamine, antitussive or throat lozenge) within the previous 8 hours.
- Those who have used a longer acting or slow release analgesic during the previous 24 hours e.g. Piroxicam and Naproxen.
- Those taking antibiotics during the previous 14 days
- Those with any painful condition that may distract attention from sore throat pain e.g. mouth ulcers etc.
- Those with a history of severe renal impairment.
- Those with a history of severe hepatic impairment
- Those taking warfarin and other coumarins.
- Those taking carbamezepine, phenobarbitone, phenytoin, primidone, rifampicin, St Johns Wort or other drugs that induce liver enzymes in the 14 days before enrolment into the study (i.e. before first dosing day).
- Those with a history of alcohol abuse or state that they regularly consume alcohol in excess of the recommended amounts (excessive alcohol >21 units per week for females and >28 units per week for males.).
- Those who are glutathione-deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.
- Those with any painful condition that requires analgesic usage.
- Those unable to refrain from smoking during their stay in the investigative site.
- Women of childbearing potential , who are pregnant or lactating, seeking pregnancy or failing to take adequate contraceptive precautions, (i.e. an oral or injectable contraceptive, an approved hormonal implant or topical patch or an intrauterine device. A women of child bearing potential is defined as any female who is less than 2 years post-menopausal or has not undergone an hysterectomy or surgical sterilisation, e.g. bilateral tubal ligation, bilateral ovariectomy (oophorectomy).
- Those previously randomised into the study.
- Those who have participated in a clinical trial in the previous 30 days. Thirty days are calculated from time of last dosing in the prior trial to time of anticipated dosing in this trial.
- Those unable in the opinion of the investigator to comply fully with the study requirements, e.g. such as those who cannot comprehend or correctly use the pain rating scales.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Investigational treatment: 8.75mg flurbiprofen micro granules or placebo granules, granules are tipped from the sachet onto the tongue and dissolve instantly. Each sachet will contain either 8.75mg of flurbiprofen or a placebo. The granules are are administered at the participant's discretion every 3 to 6 hours so long as they do not exceed the maximum recommended dose of 5 sachets per day. The participant will be provided with sufficient granules to last up to 3 days. Rescue medication: Paracetamol 500mg, 2 tablets orally, every 4 hours as required up to a maximum of 8 tablets per day. The participant will be provided with sufficient rescue medication to last up to 3 days. The resue medication is consumed in conjunction with the investigational treatment.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12609000329268